Advertisement
Canada markets open in 9 hours 4 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7303
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    82.87
    +0.06 (+0.07%)
     

  • Bitcoin CAD

    87,815.66
    -3,586.25 (-3.92%)
     

  • CMC Crypto 200

    1,386.12
    -37.98 (-2.67%)
     

  • GOLD FUTURES

    2,325.50
    -12.90 (-0.55%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,455.25
    -209.25 (-1.18%)
     

  • VOLATILITY

    15.97
    -15.69 (-49.56%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,705.39
    -754.69 (-1.96%)
     

  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

Today’s Research Reports on Fennec Pharmaceuticals, ProMIS Neurosciences, Theratechnologies and Cipher Pharmaceuticals

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / June 13, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Fennec Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=FRX.TO

ProMIS Neurosciences, Inc.
https://rdinvesting.com/news/?ticker=PMN.TO

Theratechnologies Inc.
https://rdinvesting.com/news/?ticker=TH.TO

Cipher Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=CPH.TO

ADVERTISEMENT

Fennec Pharmaceuticals' stock moved 2.95% lower Tuesday, to close the day at $13.80. The stock recorded a trading volume of 3,850 shares, which was above its three months average volume of 3,845 shares. In the last year, Fennec Pharmaceuticals' shares have traded in a range of 5.95 - 18.86. The share price has gained 131.93% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $15.05 is greater than its 200-day moving average of $13.30. Shares of Fennec Pharmaceuticals have gained approximately 7.39 percent year-to-date.

Access RDI's Fennec Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FRX.TO

On Tuesday, shares of ProMIS Neurosciences recorded a trading volume of 348,821 shares, which was above the three months average volume of 254,515 shares. The stock ended the day 8.70% higher at 0.38. The share price has gained 108.33% from its 52 week low with a 52 week trading range of 0.18 - 0.73. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.39 is greater than its 200-day moving average of $0.38. Shares of ProMIS Neurosciences have gained approximately 87.50 percent year-to-date.

Access RDI's ProMIS Neurosciences, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PMN.TO

Theratechnologies' stock had no change Tuesday, to close the day at $13.41. The stock recorded a trading volume of 214,083 shares, which was above its three months average volume of 206,781 shares. In the last year, Theratechnologies' shares have traded in a range of 4.96 - 14.75. The share price has gained 170.36% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $12.18 is greater than its 200-day moving average of $9.08. Shares of Theratechnologies have gained approximately 86.77 percent year-to-date.

Access RDI's Theratechnologies Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TH.TO

On Tuesday, shares of Cipher Pharmaceuticals recorded a trading volume of 73,530 shares, which was above the three months average volume of 43,595 shares. The stock ended the day 3.70% higher at 2.80. The stock is currently trading 51.30% below its 52 week high with a 52 week trading range of 2.65 - 5.75. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $3.44 is below its 200-day moving average of $4.11. Shares of the company are trading at a Price to Earnings ratio of 11.72. Shares of Cipher Pharmaceuticals have fallen approximately 42.86 percent year-to-date.

Access RDI's Cipher Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CPH.TO

Our Actionable Research on Fennec Pharmaceuticals Inc. (TSX :FRX.TO), ProMIS Neurosciences, Inc. (TSX :PMN.TO), Theratechnologies Inc. (TSX :TH.TO) and Cipher Pharmaceuticals Inc. (TSX :CPH.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com